In This Section      

Ciccarone Articles

Ciccarone Center Research


Gender / Cardiovascular Disease in Women

Landmark Article

The prevention of cardiovascular disease among women.
By: Michos ED.
New insights into diagnostic testing guidelines in women.
By: Metkus Jr. TS, Blumenthal RS, Joshi PH.

An update to the 2005 Guidelines on the Role of Noninvastive Testing in the Clinical Evaluation of Women with Suspected Ischemic Heart Disease was authored in response to the documented gap in appropriate diagnosis and treatment of ischemic heart disease between women and men.

Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B).
By: Swiger KJ, Martin SS, Blaha MJ, Toth PP, Nasir K, Michos ED, Gerstenblith G, Blumenthal RS, Jones SR.
The narrowing sex differential in CVD risk after midlife is mirrored by a higher total atherogenic lipoprotein cholesterol burden in women and a closer approximation of the less favorable density phenotype characteristic of men.
Read on Pubmed
Myocardial steatosis and its association with obesity and regional ventricular dysfunction: evaluated by magnetic resonance tagging and 1H spectroscopy in healthy African Americans.
By: Liu CY, Bluemke DA, Gerstenblith G, Zimmerman SL, Li J, Zhu H, Lai S, Lai H.
This study found no relationship between cardiac steatosis and left ventricular volumes or ejection fraction, though there is some evidence suggesting that cardiac steatosis may be associated with LV regional function in healthy African-American women.
Read on Pubmed
What role does genetics play in the variability in response to statin therapy?
By: Patel J, Abd T, Blumenthal RS, Nasir K, Superko R.
We examine the role of certain genetic polymorphisms in affecting the response to statin therapy.
Read on Pubmed
Sex steroid levels and response to weight loss interventions among postmenopausal women in the Diabetes Prevention Program.
By: Kim C, Barrett-Connor E, Randolph JF, Kong S, Nan B, Mather K, Golden SH and the Diabetes Prevention Program Research Group.

This study found that, among nonestrogen users, baseline sex steroids were not associated with reductions in weight or waistline circumference.

Read on Pubmed
Gender differences in coronary plaque composition and burden detected in symptomatic patients referred for coronary computed tomographic angiography.
By: Qureshi W, Blaha MJ, Nasir K, Al-Mallah MH.
This study found that symptomatic women have a lower prevalence of obstructive coronary artery disease and are less likely to have mixed coronary plaque compared to symptomatic men. Future studies are needed to determine the prognostic implications of these findings.
Read on Pubmed
Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program.
By: Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, Barrett-Connor E, Randolph JF Jr; Diabetes Prevention Program Research Group.

This study found that, among postmenopausal women, there were significant race/ethnicity differences in baseline sex hormones and changes in sex hormones.

Read on Pubmed
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy.
By: Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Randolph JF Jr, Edelstein SL, Labrie F, Buschur E, Barrett-Connor E; for The Diabetes Prevention Program Research Group.
Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormone-binding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E2). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users. We conclude that among glucose-intolerant ET users, interventions to reduce glucose are effective but possibly mediated through different pathways than among women who do not use ET.
Read on Pubmed
Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program.
By: Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Edelstein SL, Randolph JF Jr, Labrie F, Buschur E, Barrett-Connor E.
Among postmenopausal glucose-intolerant women not using estrogen, intensive lifestyle modification increased SHBG levels and lower DHEA levels. These changes are associated with lower glucose independent of adiposity and insulin. Metformin effects upon endogenous sex hormones are not significant.
Read on Pubmed